Engaging HIV Patients in Primary Care by Promoting Acceptance (HIV Engage)
|ClinicalTrials.gov Identifier: NCT02004457|
Recruitment Status : Completed
First Posted : December 9, 2013
Last Update Posted : March 9, 2017
|Condition or disease||Intervention/treatment|
|HIV||Behavioral: ABBT Other: TAU|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||43 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Engaging HIV Patients in Primary Care by Promoting Acceptance|
|Study Start Date :||March 2013|
|Primary Completion Date :||May 2016|
|Study Completion Date :||January 2017|
Experimental: Acceptance-based behavior therapy (ABBT)
ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
Placebo Comparator: Treatment-as-usual (TAU)
TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
- Frequency of attended primary care medical appointments [ Time Frame: 9 months ]The number of primary care medical appointments a participant attends over the course of 9 months.
- Acceptance and Action Questionnaire-2 [ Time Frame: 9 months ]A modified version of the Acceptance and Action Questionnaire-2 (AAQ-2) will be used to quantify the degree to which participants accept their HIV diagnosis and related stresses.
- HIV Disclosure Scale [ Time Frame: 9 months ]The HIV Disclosure Scale will be used to quantify how willing participants are to disclose their HIV status to others.
- Berger HIV Stigma Scale [ Time Frame: 9 months ]The Berger HIV Stigma Scale will used to measure the degree to which participants experience HIV-related stigma.
- Disclosure to others [ Time Frame: 9 months ]The number of individuals to whom the participant discloses his/her HIV status to.
- Social Support Questionnaire [ Time Frame: 9 months ]The Social Support Questionnaire will be used to measure participants' perceived social support.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02004457
|United States, Rhode Island|
|Providence, Rhode Island, United States, 02906|